litlas
Log inCreate account

Rafael Rosell

Active 1994–2025

245
Papers
62,327
Citations
119
h-index
239
i10-index

Citations

Citations per year for Rafael Rosell1963: 1 citations1971: 5 citations1990: 1 citations1993: 2 citations1994: 1 citations1995: 4 citations1996: 3 citations1997: 4 citations1998: 9 citations1999: 32 citations2000: 57 citations2001: 94 citations2002: 100 citations2003: 114 citations2004: 192 citations2005: 273 citations2006: 276 citations2007: 312 citations2008: 218 citations2009: 310 citations2010: 341 citations2011: 342 citations2012: 370 citations2013: 555 citations2014: 447 citations2015: 553 citations2016: 559 citations2017: 549 citations2018: 626 citations2019: 2,043 citations2020: 2,187 citations2021: 2,254 citations2022: 1,702 citations2023: 1,293 citations2024: 1,839 citations2025: 793 citations2026: 27 citations1964–1970: no citations, so these years are not shown1972–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,086 citing papers, 22.9% of this breakdownChina: 3,685 citing papers, 16.6% of this breakdownItaly: 1,206 citing papers, 5.4% of this breakdownJapan: 1,110 citing papers, 5% of this breakdownUnited Kingdom: 986 citing papers, 4.4% of this breakdownSpain: 921 citing papers, 4.2% of this breakdownFrance: 904 citing papers, 4.1% of this breakdownGermany: 869 citing papers, 3.9% of this breakdownSouth Korea: 667 citing papers, 3% of this breakdownCanada: 647 citing papers, 2.9% of this breakdownNetherlands: 533 citing papers, 2.4% of this breakdownAustralia: 447 citing papers, 2% of this breakdown
0%22.9%Other 23.2%

Institutions

Fields

  • Medicine63.9%
  • Biochemistry, Genetics and Molecular Biology28.8%
  • Immunology and Microbiology3.1%
  • Computer Science0.8%
  • Chemistry0.7%
  • Engineering0.6%
  • Other2.1%

Topics

  • Lung Cancer Treatments and Mutations14.1%
  • Lung Cancer Diagnosis and Treatment7%
  • Lung Cancer Research Studies6.2%
  • Cancer Immunotherapy and Biomarkers5%
  • Cancer Genomics and Diagnostics4.4%
  • Colorectal Cancer Treatments and Studies1.9%
  • Other61.4%

Coauthors

All papers

Open in search
  1. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    Authors: J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi - Annals of Oncology 2019 cited by 1,361

  2. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Authors: Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok - New England Journal of Medicine 2017 cited by 2,455

  3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

    Authors: Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares - The Lancet Oncology 2012 cited by 5,530

  4. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    Authors: William D. Travis, Élisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio V. Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James R. Jett, Montse Sánchez‐Céspedes, Jean‐Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio I. Wistuba, Pan‐Chyr Yang, Denise R. Aberle, Christian Brambilla, Douglas B. Flieder, Wilbur A. Franklin, Adi F. Gazdar, Michael K. Gould, P S Hasleton, Douglas W. Henderson, Bruce Johnson, David Johnson, Keith M. Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor L. Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming‐Sound Tsao, David Yankelewitz - Journal of Thoracic Oncology 2011 cited by 4,843

  5. Non-small-cell lung cancer

    Authors: Cesare Gridelli, Antônio Rossi, David P. Carbone, Juliana Guarize, Niki Karachaliou, Tony Mok, Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell - Nature Reviews Disease Primers 2015 cited by 1,095

  6. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Authors: Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti, Jean-Yves Douillard, Frances A. Shepherd, Richard Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour, Stephen Spiro, Estelle Rolland, Roldano Fossati, D. Aubert, Keyue Ding, David Waller, Thierry Le Chevalier - Journal of Clinical Oncology 2008 cited by 2,670

  7. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

    Authors: Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok - The Lancet Oncology 2017 cited by 1,210

  8. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

    Authors: Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, D.-W. Kim, M. Pérol, S.-H.I. Ou, Jin Seok Ahn, A. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, Johannes Noé, Solange Peters - Annals of Oncology 2020 cited by 686

  9. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    Authors: Rafael Rosell, Teresa Morán, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo López-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massutí, J.L. González-Larriba, Luis Paz‐Ares, Isabel Bover, Rosario García‐Campelo, Miguel Ángel Moreno, Sílvia Catot, Christian Rolfo, Noemı́ Reguart, Ramón Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Ángel Molina‐Vila, José Javier Sánchez, Miquel Tarón - New England Journal of Medicine 2009 cited by 2,377

  10. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

    Authors: Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D. Levine, Jin Kyung Rho, Yun Jung Choi, Chang‐Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung‐Shin Lee, Vincent A. Miller, Maria E. Arcila, Marc Ladanyi, Philicia Moonsamy, Charles L. Sawyers, Titus J. Boggon, C. Patrick, Carlota Costa, Miquel Tarón, Rafael Rosell, Balázs Halmos, Trever G. Bivona - Nature Genetics 2012 cited by 1,220

  11. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

    Authors: Luping Lin, Amit J. Sabnis, Elton Chan, Victor Olivas, Lindsay Cade, Evangelos Pazarentzos, Saurabh Asthana, Dana S. Neel, Jenny Yan, Xinyuan Lu, Luu Pham, Mingxue M Wang, Niki Karachaliou, María González Cao, José Luís Manzano, José Luis Ramírez, J.M. Sanchez Torres, Fiamma Buttitta, Charles M. Rudin, Eric A. Collisson, Alain P. Algazi, Eric M. Robinson, Iman Osman, Eva Muñoz‐Couselo, Javier Cortés, Dennie T. Frederick, Zachary A. Cooper, Martin McMahon, Antonio Marchetti, Rafael Rosell, Keith T. Flaherty, Jennifer A. Wargo, Trever G. Bivona - Nature Genetics 2015 cited by 553

  12. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

    Authors: Brendan Bulik‐Sullivan, Jennifer Busby, Christine D. Palmer, Matthew J. Davis, Tyler Murphy, Andrew P. Clark, Michele Busby, Fujiko Duke, Aaron Yang, Lauren Young, Noelle C Ojo, Kamilah Caldwell, Jesse Abhyankar, Thomas Boucher, Meghan G. Hart, Vladimir Makarov, Vincent de Montpréville, Olaf Mercier, Timothy A. Chan, Giorgio V. Scagliotti, Paolo Bironzo, Silvia Novello, Niki Karachaliou, Rafael Rosell, Ian C. Anderson, Nashat Gabrail, John Hrom, Chainarong Limvarapuss, Karin Choquette, Alexander I. Spira, Raphaël F. Rousseau, Cynthia Voong, Naiyer A. Rizvi, Élie Fadel, Mark G. Frattini, Karin Jooss, Mojca Škoberne, Joshua M. Francis, Roman Yelensky - Nature Biotechnology 2018 cited by 310

  13. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Authors: Nasser H. Hanna, Bryan J. Schneider, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, Ishmael Jaiyesimi, David H. Johnson, Natasha B. Leighl, Tanyanika Phillips, Gregory J. Riely, Andrew Robinson, Rafael Rosell, Joan H. Schiller, Navneet Singh, David R. Spigel, Janis O. Stabler, Joan Tashbar, Gregory A. Masters - Journal of Clinical Oncology 2020 cited by 455

  14. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets

    Authors: Myron G. Best, Nik Sol, Sjors G. J. G. In ‘t Veld, Adrienne Vancura, Mirte Muller, Anna-Larissa N. Niemeijer, Aniko V. Fejes, Lee-Ann Tjon Kon Fat, Anna E. Huis in ‘t Veld, Cyra E Leurs, Tessa Y. Le Large, Laura L. Meijer, Irsan Kooi, François Rustenburg, Pepijn Schellen, Heleen Verschueren, Edward P. Post, Laurine E. Wedekind, Jillian Wilhelmina Paulina Bracht, Michelle Esenkbrink, Leon J. Wils, Francesca Favaro, Jilian D. Schoonhoven, Jihane Tannous, Hanne Meijers‐Heijboer, Geert Kazemier, Elisa Giovannetti, Jaap C. Reijneveld, Sander Idema, Joep Killestein, Michal Heger, Saskia C.A. de Jager, Rolf T. Urbanus, Imo E. Hoefer, Gerard Pasterkamp, Christine Mannhalter, Jose Gomez‐Arroyo, Harm Jan Bogaard, David P. Noske, W. Peter Vandertop, Daan van den Broek, Bauke Ylstra, R. Jonas A. Nilsson, Pieter Wesseling, Niki Karachaliou, Rafael Rosell, Elizabeth Lee-Lewandrowski, Kent Lewandrowski, Bakhos A. Tannous, Adrianus J. de Langen, Egbert F. Smit, Michel M. van den Heuvel, Thomas Würdinger - Cancer Cell 2017 cited by 333

  15. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Authors: Nasser H. Hanna, Andrew Robinson, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, Ishmael Jaiyesimi, David H. Johnson, Natasha B. Leighl, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, Navneet Singh, David R. Spigel, Joan Tashbar, Gregory A. Masters - Journal of Clinical Oncology 2021 cited by 301

  16. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations

    Authors: Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Min Lee, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Yi‐Long Wu - Journal of Clinical Oncology 2018 cited by 436

  17. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

    Authors: Shirish M. Gadgeel, Solange Peters, Tony Mok, Alice T. Shaw, D.W. Kim, Sai‐Hong Ignatius Ou, M. Pérol, Anna Wrona, Silvia Novello, Rafael Rosell, Ali Zeaiter, Tian Liu, Eveline Nüesch, Bogdan Balas, D. Ross Camidge - Annals of Oncology 2018 cited by 324

  18. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

    Authors: Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth Blanchard, Julie R. Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy B. Elkins, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, David H. Johnson, Natasha B. Leighl, Hirva Mamdani, Gregory A. Masters, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Andrew Robinson, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, David R. Spigel, Ishmael Jaiyesimi - Journal of Clinical Oncology 2022 cited by 124

  19. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

    Authors: Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth Blanchard, Julie R. Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy B. Elkins, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, David H. Johnson, Natasha B. Leighl, Hirva Mamdani, Gregory A. Masters, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Andrew Robinson, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, David R. Spigel, Ishmael Jaiyesimi - Journal of Clinical Oncology 2022 cited by 113

  20. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

    Authors: Élisabeth Brambilla, Gwénaël Le Teuff, Sophie Marguet, Sylvie Lantuéjoul, Ariane Dunant, Stephen L. Graziano, Robert Pirker, Jean-Yves Douillard, Thierry Le Chevalier, Martin Filipits, Rafael Rosell, Robert A. Kratzke, Helmut Popper, Jean‐Charles Soria, Frances A. Shepherd, Lesley Seymour, Ming‐Sound Tsao - Journal of Clinical Oncology 2016 cited by 361

  21. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

    Authors: Jean‐Yves Douillard, Rafael Rosell, Mario De Lena, Francesco Carpagnano, Rodryg Ramlau, Jose Luis Gonzáles-Larriba, Tomasz Grodzki, José Rodrigues Pereira, A. Le Groumellec, Vito Lorusso, C. Clary, Antonio J. Torres, Jabrail Dahabreh, Pierre‐Jean Souquet, Julio Astudillo, P. Fournel, Á. Artal, Jacek Jassem, Leona Koubková, Patricia His, M Riggi, P Hurteloup - The Lancet Oncology 2006 cited by 1,588

  22. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

    Authors: Julien Mazières, Fabrice Barlési, Thomas Filleron, Benjamin Besse, I. Monnet, Michèle Beau‐Faller, Solange Peters, Éric Dansin, Martin Früh, Miklos Pless, Rafael Rosell, Marie Wislez, P. Fournel, Virginie Westeel, Federico Cappuzzo, Alexis B. Cortot, Denis Moro‐Sibilot, Julie Milia, Oliver Gautschi - Annals of Oncology 2015 cited by 330

  23. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

    Authors: Enriqueta Felip, Rafael Rosell, J Maestre, José Manuel Rodríguez-Paniagua, Teresa Morán, Julio Astudillo, Guillermo Alonso, José Manuel Borro, J.L. González-Larriba, Antonio Torres, Carlos Camps, R. Guijarro, Dolores Isla, Rafael Aguiló, Vicente Alberola, José Padilla, Abel Sánchez‐Palencia, José Javier Sánchez, Eduardo Hermosilla, Bartomeu Massutí - Journal of Clinical Oncology 2010 cited by 430

  24. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

    Authors: Óscar Arrieta, Feliciano Barrón, Laura Alejandra Ramírez-Tirado, Zyanya Lucía Zatarain-Barrón, Andrés F. Cardona, Diego A. Díaz-García, Masao Yamamoto Ramos, Beatriz Mota-Vega, Amir Carmona, Marco Polo Peralta Álvarez, Yolanda Bautista, Fernando Aldaco, Raquel Gerson, Christian Rolfo, Rafael Rosell - JAMA Oncology 2020 cited by 153